0.45
+2.27%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medicenna Therapeutics
Its shares trade on Toronto Stock Exchange under the ticker MDNA.TO. It has been listed since 13 July 2015.
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The firm focuses on commercialization EC and Superkines for the treatment of cancer. The firm's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The firm's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Jul 2015
- Employees
- 7
- Website
- medicenna.com ↗
Leadership
Pay as last reported
- Dr. Fahar MerchantChairman of the Board, President, Chief Executive Officer, since 2011C$1.3m
- Mr. David HymanChief Financial Officer, Corporate SecretaryC$446,000
- Ms. Rosemina MerchantChief Development Officer, since 2016C$982,800
- Mr. Albert BeraldoLead Independent DirectorC$234,500
- Ms. Karen DawesIndependent DirectorC$202,000
- Dr. John GeltoskyIndependent DirectorC$202,000
- Mr. Karim LaljiIndependent DirectorC$167,000
- Dr. John SampsonIndependent DirectorC$192,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 46
- Social
- 57
- Governance
- 28
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medicenna Therapeutics Corp possesses a comprehensive and valuable intellectual property portfolio, which includes patents and patent applications covering their innovative technologies and products. This provides them with a competitive advantage and potential revenue streams through licensing agreements or commercialization of their intellectual property.
- Medicenna Therapeutics Corp has a robust pipeline of novel therapeutic candidates targeting various types of cancers and diseases. Their innovative approach and research expertise have the potential to revolutionize the treatment options available in the healthcare industry, thereby attracting interest and collaborations from potential partners and investors.
- With a dedicated team of experienced scientists and researchers, Medicenna Therapeutics Corp possesses strong research and development capabilities. This allows them to efficiently and effectively progress their therapeutic candidates through preclinical and clinical development stages, increasing the likelihood of successful commercialization.
Weaknesses
- Medicenna Therapeutics Corp heavily relies on external funding sources, such as grants, partnerships, and investment capital, to support their R&D activities. This makes them vulnerable to economic fluctuations, market conditions, and potential limitations in securing adequate funding, which could impact their operations and pipeline progression.
- Most of Medicenna Therapeutics Corp's therapeutic candidates are still in the early stages of development, including preclinical and Phase 1 clinical trials. The inherent risks associated with early-stage development, such as regulatory hurdles, efficacy, and safety concerns, pose challenges and uncertainties in successfully advancing these candidates to later stages and commercialization.
- Despite their promising pipeline, Medicenna Therapeutics Corp currently has limited market presence and recognition. Competing against established pharmaceutical companies with greater resources and established market share poses a challenge in gaining market acceptance and adoption of their innovative therapies.
Opportunities
- The healthcare industry is witnessing an increasing demand for more effective and personalized therapeutic options, particularly in the field of oncology. Medicenna Therapeutics Corp's innovative pipeline aligns well with this growing demand, positioning them to capture a significant market share and become a key player in the industry.
- Forming strategic partnerships and collaborations with established pharmaceutical companies, research institutions, and regulatory agencies can provide Medicenna Therapeutics Corp with access to additional resources, expertise, and regulatory support. These partnerships can accelerate their pipeline development, enhance market reach, and strengthen their position in the industry.
- The potential applications of Medicenna Therapeutics Corp's innovative technologies and therapeutic candidates extend beyond oncology, offering opportunities to expand into other disease areas. This diversification can broaden their market potential, increase revenue streams, and reduce the dependency on a single therapeutic area.
Threats
- The pharmaceutical industry is heavily regulated, and the development and commercialization of new therapies require compliance with rigorous standards and regulations. Medicenna Therapeutics Corp may face challenges in navigating the complex regulatory landscape, which can delay or hinder the approval process of their therapeutic candidates.
- The healthcare and biotech industry is highly competitive, with numerous companies vying for market share and investment opportunities. Medicenna Therapeutics Corp faces competition from established pharmaceutical companies, as well as other emerging biotech companies with similar innovative technologies and pipeline candidates. Sustaining a competitive advantage and differentiating themselves becomes crucial for success.
- Economic downturns, market fluctuations, and global pandemics can significantly impact the healthcare industry and investor sentiment. Medicenna Therapeutics Corp may face challenges in securing funding, attracting investments, and maintaining steady revenue streams during periods of economic and market volatility, potentially affecting their pipeline progression and operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.